Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I’ve followed you for awhile since you like bio stocks like me. I’m surprised I haven’t seen you over at cydy ?
Also I’m long on BLRX.
Can any advice for a new bio investor?!
(Reuters) - Regeneron Pharmaceuticals said on Friday it would stop enrolling patients receiving advanced COVID-19 care in a trial testing its experimental antibody treatment in hospitalized patients, based on the recommendation of an independent safety board.
The recommendation was based on a potential safety signal and an unfavorable risk-benefit profile at this time, the company said. Rival Eli Lilly & Co stopped enrolling such patients based on a similar suggestion earlier this week.
“It appears a trend is emerging in the class, and it may be that neutralizing antibodies simply do not work and/or are not safe in this (hospitalized) population,” JP Morgan analyst Cory Kasimov said in a note.
https://www.reuters.com/article/us-health-coronavirus-regeneron-pharms/regeneron-to-stop-enrolling-very-sick-covid-19-patients-in-antibody-trials-idUSKBN27F2AY
JW2020: I think it's the treatment they're more involved in. However, I might be mistaken
If they are failing in their bid to produce an acceptable vaccine then why did get the contract??
$REGN One in Three Americans Would Not Get COVID-19 Vaccine
https://news.gallup.com/poll/317018/one-three-americans-not-covid-vaccine.aspx
$REGN Why A Vaccine Won’t Be a Quick Fix for COVID-19
https://www.webmd.com/lung/news/20200903/why-a-vaccine-wont-be-a-quick-fix-for-covid-19
Regeneron Pharmaceuticals, Gilead Sciences Shares Rise As Their Therapies Used To Treat President
https://www.investors.com/news/technology/regn-stock-gild-stock-up-drugs-used-treat-president-trump/ $REGN $GILD
Don't know why the stock has been going down, in spite of the fact that Trump constantly refers to the fact that it saved his life
Could it be that the vaccine will be given away free to first responders and seniors.
Anyway, as I mentioned before they have a great pipeline.
How efficacious is Inmazeb? Anyone have a link?
REGN has a great pipeline of drugs - the one Trump has been taking is icing on the cake
Let’s go, to the moon!!!!
$REGN $GILD Trump says he hopes to hold rally Saturday despite recent COVID-19 diagnosis
https://thehill.com/homenews/administration/520315-trump-says-he-hopes-to-hold-rally-saturday-despite-recent-covid-19
$REGN $GILD Trump says he hopes to hold rally Saturday despite recent COVID-19 diagnosis
https://thehill.com/homenews/administration/520315-trump-says-he-hopes-to-hold-rally-saturday-despite-recent-covid-19
Artistic: free is great but doesn't bring in revenue
you all are some sick-o's, 'aborted' baby parts in this company shots!
this is what saved trump from death A, that the cdc says 74 year olds have a 94% chance to survive from..
the 'rich' still eating babys...
Let see if this get approved soon
Congrats to everyone who owns shares, this is gonna pop. I just saw a message from President Trump that he thinks Regeneron should be offered for free to everyone in America who has Covid. Said it's a therapeutic that cured him and he feels great. So now here I am checking out the stock price and seeing it already going up after hours.
You're not the only one who feels that way:
https://www.bitchute.com/video/NUwgvJJQqY8/
$REGN $GILD White House: Trump given Gilead Sciences' remdesivir, in addition to Regeneron drug
https://www.marketwatch.com/story/white-house-trump-given-gilead-sciences-remdesivir-in-addition-to-regeneron-drug-2020-10-03
The coordination and lockstep transparency was hard to ignore. A 2nd draft here would strike through “scripted” and call it a consumer confidence performance.
$REGN hoping this helps Trump recover fully!!
Has anyone seen ENZC? That has final stage monoclonal antibody!
I’m curious of the comparison. Check it out if you want.
BioClonetics is in the final stage of development of a parent monoclonal antibody.
https://finance.yahoo.com/news/enzolytics-inc-announces-board-member-130000555.html
https://twitter.com/dangleburries/status/1312145738395131904?s=21
He got his second treatment yesterday and seems to be doing well.
but then he's the energize bunny anyway.
Why do you think it feels scripted?
Hopefuly this treatment will help the President to recover fully.
This leaked treatment memo certainly ads layers to my speculation here and of the Trump admins actions over the course of the last 48 hrs. I cut media strategies for a living and will tell you: this all feels scripted.
President Trump treated with REGN-COV2 Antibody Cocktail
along with zinc and vitamin D.
https://www.forexlive.com/news/!/trump-treated-with-regeneral-antibody-cocktail-has-low-grade-fever-20201002
New article mentioning $REGN
Why major pharmaceutical and biotech companies will keep growing for years
https://pennystocks.news/why-major-pharmaceutical-and-biotech-companies-will-keep-growing-for-years-gild/
Chinese (Ling et al) Convalescent Plasma fail published in 8/4 JAMA sheds doubt on REGN Plasma therapy (contains CP) and puts more importance on NIAID HGEN-GILD BET trial.
News: $REGN Is Regeneron a Good Coronavirus Stock to Buy?
Excitement for Regeneron 's (NASDAQ: REGN) potential new coronavirus treatment has been soaring along with the stock's price, and investors are wondering how much further it can climb. Is Regeneron a good coronavirus stock to buy now, or has the stock market's enthusiasm for this coronavirus...
Got this from REGN - Is Regeneron a Good Coronavirus Stock to Buy?
Regeneron Awards recently:
Fortune: Best Companies to Work for, 2020
Newsweek, America’s Most Responsible Companies, 2020
IDEA Pharma, Pharmaceutical Invention Index, 2019
RobecoSAM and S&P Dow Jones Indices: Dow Jones Sustainability World Index, 2019
Science: Top Employer, 2019
Harvard Business Review: Best Performing CEOs, 2019
Civic 50: Most Community-Minded Companies in the Nation, 2019
Fast Company: Best Workplaces for Innovators, 2019
Shingo Institute: The Shingo Prize, 2019
Great Places to Work: Best Workplace in Ireland, 2019
Forbes: Top 10 Most Innovative Companies, 2018
Better Coronavirus Stock: Sorrento Therapeutics vs. Regeneron
It's a battle of big vs. little with these two COVID-19-focused biotechs.
Keith Speights (TMFFishBiz)
Jun 16, 2020 at 6:51AM
In case you haven't noticed, antibody therapies are all the rage when it comes to developing potential treatments for COVID-19. Two companies in the thick of the race with experimental novel-coronavirus antibody therapies are Sorrento Therapeutics (NASDAQ:SRNE) and Regeneron Pharmaceuticals (NASDAQ:REGN).
Both biotech stocks have been big winners so far in 2020. Sorrento's shares have skyrocketed more than 50%, while Regeneron is up more than 40%. Which of these coronavirus-focused stocks is the better pick for long-term investors?
Gloved hand separating fallen wooden dominoes spelling out COVID19 from a set of standing dominoesIMAGE SOURCE: GETTY IMAGES.
The case for Sorrento Therapeutics
Two potential COVID-19 cures waiting in the wings? That's how Sorrento Therapeutics CEO Henry Ji might put it. After Sorrento first announced in May that it had identified an antibody that could completely neutralize SARS-CoV-2, Ji went on TV saying that his company could be on track to have a cure for COVID-19.
Earlier this month, Sorrento reported that another antibody, discovered in March, also demonstrated the ability to completely inhibit the novel coronavirus. These two antibodies that could potentially serve as antidotes to COVID-19 aren't the only coronavirus programs that Sorrento is working on, though.
The company recently submitted an application to the Food and Drug Administration for Emergency Use Authorization for its COVI-TRACK in vitro diagnostic test for detecting COVID-19 antibodies. It's collaborating with Mount Sinai Health System in New York City to develop COVID-19 antibody cocktail therapies. Sorrento also launched an effort to develop a COVID-19 vaccine.
None of Sorrento's COVID-19 antibody therapy or vaccine candidates have advanced beyond preclinical testing yet. However, the biotech's pipeline includes five clinical-stage programs that aren't related to the coronavirus. Its lead candidate, resiniferatoxin (RTX), is being evaluated in phase 2 clinical studies for treating the pain of terminal cancer and pain associated with osteoarthritis. Sorrento also has three cancer immunotherapies in early-stage development.
The biggest argument for buying Sorrento shares is that pretty much any success would likely be a major catalyst. Sorrento's market cap is currently around $1 billion. All it would take for the biotech to take off would be some positive news from planned clinical testing of its COVID-19 programs.
The case for Regeneron
Regeneron is mounting a fight against COVID-19 on two fronts. The company and its partner Sanofi are evaluating rheumatoid arthritis drug Kevzara in a phase 2/3 study for treating patients with respiratory illness caused by COVID-19. After a review by the study's Independent Data Monitoring Committee in late April, the trial refocused only on more critical patients.
Last week, Regeneron began a phase 1 clinical study evaluating an antibody cocktail for both preventing and treating COVID-19. The biotech thinks that this antibody cocktail could be available much sooner than a vaccine, and treat patients already diagnosed with the novel coronavirus disease. It also anticipates that the cocktail could be helpful for elderly and immunocompromised patients who don't respond well to COVID-19 vaccines.
Unlike Sorrento, Regeneron doesn't need its COVID-19 programs to go well to be successful. The company raked in $1.83 billion in sales in the first quarter of 2020, up 33% year over year. It's already quite profitable, with earnings soaring 36% year over year in Q1 to $625 million.
Regeneron claims multiple big winners in its lineup. Sales continue to climb for blockbuster eye-disease drug Eylea. Momentum is picking up strongly for immunology drug Dupixent. Recent positive clinical results for Libtayo could lead to expanded indications for the immunotherapy, as a first-line treatment for non-small cell lung cancer and as a second-line treatment for advanced basal cell carcinoma.
Meanwhile, Regeneron's pipeline is loaded with candidates that could pave the way for future growth. The company has eight late-stage programs, 12 phase 2 programs, and 10 phase 1 programs (including its COVID-19 antibody cocktail).
The better coronavirus stock
You've probably heard the old expression that "a bird in the hand is worth two in the bush." I think that adage applies to the choice between Sorrento and Regeneron.
Sorrento has some intriguing candidates, but they're all early in development. Regeneron has several successful drugs already on the market, plus a deep pipeline. Sorrento could potentially become a big winner; Regeneron already is a big winner. And with its antibody cocktail already in clinical testing, it has a big head start over Sorrento on the COVID-19 front.
Regeneron is the better coronavirus stock. It's the better stock, period.
$REGN Taking Winnebago Options for a Ride -- https://www.barrons.com/articles/taking-winnebago-options-for-a-ride-51592474402
$REGN vs $GILD Better Coronavirus Stock: Gilead Sciences or Regeneron Pharmaceuticals?
If a safe and effective treatment for COVID-19 is close at hand, it will likely come from one of these two biotechs. https://www.fool.com/investing/2020/03/19/better-coronavirus-stock-gilead-sciences-or-regene.aspx
$REGN and $GILD merger? Both working on #Covid19 pipeline. GILD has 1 FDA approval already. I believe only one in the world.
Morning Bell With Jim Cramer: Amazon, Boeing, Regeneron
AMZN BA REGN MRNA
Jim Cramer shares stock market news including Amazon coming after small businesses, Boeing 737 Max being ready and Regeneron or Moderna as the vaccine pick.
https://www.thestreet.com/investing/morning-bell-with-jim-cramer-amazon-boeing-regeneron
Even GILD was down after 3:56 pm PR from FDA on 5/1/2020, issuing an Emergency Use Authorization (EUA) for Remdesivir in treating patients presenting with CovD-19.
Regeneron is subject of rumors that it has a mab that will be used in near-term clinical trials with R.
Another vaccine that will get to market faster. Despite the assumption that a Covid-19 vaccine is at least a year away, Oxford University has developed a vaccine (ChAdOx1 nCoV-19) that may be ready by the fall. The Oxford scientist in charge (Professor Sarah Gilbert) said her team has gone through stages of vaccine development that usually take 5 years in just 4 months. She also said she is 80% confident that the vaccine will work. And Merck KGaA (MKKGY) has signed up to help manufacture the vaccine. Why hasn’t this stock popped more than it has? Is it confusion over another Merck (MRK) that is NOT involved? The fact that it’s a German company trading here as an ADR? https://www.nytimes.com/reuters/2020/04/17/world/asia/17reuters-health-coronavirus-vaccine-oxford.html ; https://www.emdgroup.com/en/news/jenner-milestone-covid-19-vaccine-manufacturing-14-04-2020.html
Another vaccine that will get to market faster. Despite the assumption that a Covid-19 vaccine is at least a year away, Oxford University has developed a vaccine (ChAdOx1 nCoV-19) that may be ready by the fall. The Oxford scientist in charge (Professor Sarah Gilbert) said her team has gone through stages of vaccine development that usually take 5 years in just 4 months. She also said she is 80% confident that the vaccine will work. And Merck KGaA (MKKGY) has signed up to help manufacture the vaccine. Why hasn’t this stock popped more than it has? Is it confusion over another Merck (MRK) that is NOT involved? The fact that it’s a German company trading here as an ADR? https://www.nytimes.com/reuters/2020/04/17/world/asia/17reuters-health-coronavirus-vaccine-oxford.html ; https://www.emdgroup.com/en/news/jenner-milestone-covid-19-vaccine-manufacturing-14-04-2020.html
Another vaccine that will get to market faster. Despite the assumption that a Covid-19 vaccine is at least a year away, Oxford University has developed a vaccine (ChAdOx1 nCoV-19) that may be ready by the fall. The Oxford scientist in charge (Professor Sarah Gilbert) said her team has gone through stages of vaccine development that usually take 5 years in just 4 months. She also said she is 80% confident that the vaccine will work. And Merck KGaA (MKKGY) has signed up to help manufacture the vaccine. Why hasn’t this stock popped more than it has? Is it confusion over another Merck (MRK) that is NOT involved? The fact that it’s a German company trading here as an ADR? https://www.nytimes.com/reuters/2020/04/17/world/asia/17reuters-health-coronavirus-vaccine-oxford.html ; https://www.emdgroup.com/en/news/jenner-milestone-covid-19-vaccine-manufacturing-14-04-2020.html
Another vaccine that will get to market faster. Despite the assumption that a Covid-19 vaccine is at least a year away, Oxford University has developed a vaccine (ChAdOx1 nCoV-19) that may be ready by the fall. The Oxford scientist in charge (Professor Sarah Gilbert) said her team has gone through stages of vaccine development that usually take 5 years in just 4 months. She also said she is 80% confident that the vaccine will work. And Merck KGaA (MKKGY) has signed up to help manufacture the vaccine. Why hasn’t this stock popped more than it has? Is it confusion over another Merck (MRK) that is NOT involved? The fact that it’s a German company trading here as an ADR? https://www.nytimes.com/reuters/2020/04/17/world/asia/17reuters-health-coronavirus-vaccine-oxford.html ; https://www.emdgroup.com/en/news/jenner-milestone-covid-19-vaccine-manufacturing-14-04-2020.html
$REGN is the most promising for a CoronaVirus treatment:
https://www.statnews.com/2020/03/17/regeneron-covid-19-trials-summer/
z
Crazy volatility even for a biotech with COVID19 product in the works.
Was the reading the PR news on this one this week, since I take an RA drug.....
I was thinking 2 weeks ago, based on my Bio-engineering-Bio-Chem back ground (my older brother mentor was an MD) that RA drugs, Immune suppressants might just limit the COVID19 damage, if I got unlucky and caught it.
Problem is taking it makes me an easy target for COVID19, but taking it protects my joints (I have the RA version of arthritis, bad shit), and may just limit lung damage since most of the Covid19 damage is done by the immune systems over response of trying to kill the virus.
That PR this week got my attention (COvid19/Biotech news) and bang there is, the big boys thinking the same thing I was.
Which reminds me that VEP-Lipsome in a drink by Milv has solid potential for limiting and repair lung cell tissue damage from Covid19 as well. Hang on to those shares tight sir, as the past research says I am right, so if Milv/NDT Pharma comes out with a covid19 supplement drink line approved by UPennMed doctors (the JV partners with Milv) that price could explode 50 fold in days.
I hope to interview management (ungaged management) in a week or so and report back to folks since the Custodian was relieved today, from what I heard(??)
This is the best news I’ve ever read... and nobody is active on this board.... crazy
http://ih.advfn.com/stock-market/NASDAQ/regeneron-pharmaceuticals-REGN/stock-news/81706209/eylea-aflibercept-injection-reduced-risk-of-devel
News: $REGN First Clinical Data for REGN5458 (BCMAxCD3) Show Positive Preliminary Results in Multiple Myeloma
TARRYTOWN, N.Y. , Dec. 8, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced initial clinical data for REGN5458, a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory (R/R) multiple myeloma. BCMA (B-cell maturation antigen) is...
Read the whole news REGN - First Clinical Data for REGN5458 (BCMAxCD3) Show Positive Preliminary Results in Multiple Myeloma
Followers
|
35
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
242
|
Created
|
01/16/03
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |